BDBM50185235 CHEMBL3823836::US20230322822, Control compound 2

SMILES COc1cc(N2CCC(CC2)N2CCN(C)CC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1

InChI Key InChIKey=FXYPQFBJRKMLDS-UHFFFAOYSA-N

Data  16 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 50185235   

TargetInsulin receptor(Human)
Ariad Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 171nMAssay Description:Inhibition of human InsR using myelin basic protein as substrate and [gamma-33P]ATP measured after 1 hrMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2017
Entry Details Article
PubMed
TargetInsulin-like growth factor 1 receptor(Human)
Ariad Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 27nMAssay Description:Inhibition of human IGF1R using KKKSPGEYVNIEFG as substrate and [gamma-33P]ATP measured after 1 hrMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2017
Entry Details Article
PubMed
TargetALK tyrosine kinase receptor(Human)
Ariad Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 0.860nMAssay Description:Inhibition of human ALK using poly[Glu:Tyr] (4:1) as substrate and [gamma-33P]ATP measured after 1 hrMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/3/2017
Entry Details Article
PubMed
TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Chengdu Di''Ao Jiuhong Pharmaceutical Factory

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 250nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Chengdu Di''Ao Jiuhong Pharmaceutical Factory

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 250nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,T790M](Human)
Chengdu Di''Ao Jiuhong Pharmaceutical Factory

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 250nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [T790M,L858R](Human)
Chengdu Di''Ao Jiuhong Pharmaceutical Factory

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 250nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Chengdu Di''Ao Jiuhong Pharmaceutical Factory

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 250nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,T790M,C797S](Human)
Chengdu Di''Ao Jiuhong Pharmaceutical Factory

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 250nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Chengdu Di''Ao Jiuhong Pharmaceutical Factory

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 250nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
Go to US Patent

TargetALK tyrosine kinase receptor/Echinoderm microtubule-associated protein-like 4(Human)
Chengdu Di''Ao Jiuhong Pharmaceutical Factory

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 250nMAssay Description:To assess the effect of compounds on the activity of EML4-ALK kinases, kinase activity was tested by measuring ATP consumption in an enzymatic reacti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,T790M](Human)
Chengdu Di''Ao Jiuhong Pharmaceutical Factory

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 172nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,C797S](Human)
Chengdu Di''Ao Jiuhong Pharmaceutical Factory

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 177nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [L858R,T790M,C797S](Human)
Chengdu Di''Ao Jiuhong Pharmaceutical Factory

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 583nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor [1-18,20-1210,T790M,C797S](Human)
Chengdu Di''Ao Jiuhong Pharmaceutical Factory

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 221nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Chengdu Di''Ao Jiuhong Pharmaceutical Factory

US Patent
LigandPNGBDBM50185235(CHEMBL3823836 | US20230322822, Control compound 2)
Affinity DataIC50: 1.76E+3nMAssay Description:To assess the effect of compounds on the activity of wild-type and mutant EGFR kinases, kinase activity was tested by measuring ATP consumption in an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2023
Entry Details
Go to US Patent